XERS 8-K 2026-11-02

Xeris Biopharma Holdings, Inc. (XERS) 8-K dated 2026-11-02 — accession 0001867096-26-000095.

Xeris Biopharma Holdings, Inc. (XERS) is a biotechnology company listed on US.

Xeris Biopharma Holdings, Inc. filed a 8-K on 2026-11-02. Accession 0001867096-26-000095.

This 8-K covers: Director/officer change (Item 5.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported XERS revenue for 2025-12-31 was $291.8M. Net income was $554.0K. Revenue was up 43.7% from 2024-12-31 to 2025-12-31. XERS currently screens at market cap $760.7M.

Not investment advice. The XERS SEC hub lists recent forms. The stock page is the research view.